share_log

拜登减肥药医保计划推动礼来上涨,安进因试验结果不佳下跌

Securities Times ·  Nov 27 08:18

转自:证券时报

证券时报网讯,周二,拜登政府计划将减肥药纳入医保和补助计划,导致诺和诺德和礼来的股价上涨。然而,安进公司的减肥药MariTide因副作用较高且试验结果未能满足市场预期,股价大跌。尽管MariTide在一年试验中帮助非糖尿病患者最多减重20%,与礼来的Zepbound效果相当,但约11%的患者因副作用退出试验,显著高于礼来的7%。

校对:王锦程

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment